体外膜氧合治疗COVID-19与甲型H1N1流感相关急性呼吸窘迫综合征:多中心回顾性队列研究
这项多中心回顾性队列研究纳入2009至2021年意大利7个ICU中因COVID-19或甲型H1N1肺炎相关ARDS接受静脉-静脉ECMO的成人患者,比较两组结局。主要终点为ECMO启动后60天全因死亡率:COVID-19组估计累积死亡率为46%,高于H1N1组的27%(HR 1.76,95%CI 1.17-2.46)。校正年龄和ECMO前住院时长后,HR降至1.39(95%CI 0.78-2.47),差异不再显著。COVID-19组的ICU住院时长、住院时长、ECMO和侵入性机械通气时长以及ECMO相关出血并发症均高于H1N1组。
要点
- ECMO启动后60天未校正累积死亡率:COVID-19组46% vs H1N1组27%,HR 1.76(95%CI 1.17-2.46)。
- 校正年龄和ECMO前住院时长后,HR降至1.39(95%CI 0.78-2.47),差异未达统计学显著。
- 年龄较大和ECMO前住院时间较长是可解释上述死亡率差异的重要协变量。
- COVID-19组的ICU住院时长、住院时长、ECMO和侵入性机械通气时长均高于H1N1组。
- COVID-19组ECMO相关出血并发症高于H1N1组。
适用人群与场景
- 2009至2021年意大利7个ICU中因COVID-19或甲型H1N1肺炎相关ARDS接受静脉-静脉ECMO的成人患者,共308例(COVID-19组146例,H1N1组162例)。
研究设计与关键结果
- 研究类型:多中心回顾性队列研究,纳入308例接受ECMO支持的ARDS患者(COVID-19组146例,H1N1组162例),来自意大利7个ICU,时间跨度为2009至2021年。
- 主要终点:ECMO启动后60天全因死亡率,COVID-19组估计累积死亡率为46%,H1N1组为27%,HR 1.76(95%CI 1.17-2.46)。
- 多变量Cox模型校正年龄和ECMO前住院时长后,HR降至1.39(95%CI 0.78-2.47),差异未达统计学显著。
- 次要终点:COVID-19组的ICU住院时长、住院时长、ECMO时长和侵入性机械通气时长均高于H1N1组;COVID-19组ECMO相关出血并发症高于H1N1组。
- 90天死亡率作为次要终点,原文未报告具体数值。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于因COVID-19或甲型H1N1肺炎相关ARDS接受静脉-静脉ECMO的成人患者,未校正的60天死亡率COVID-19组高于H1N1组,但校正年龄和ECMO前住院时长后差异无统计学意义,提示年龄较大和ECMO前住院时间较长可能解释死亡率差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) has become an established rescue therapy for severe acute respiratory distress syndrome (ARDS) in several etiologies including influenza A H1N1 pneumonia. The benefit of receiving ECMO in coronavirus disease 2019 (COVID-19) is still uncertain. The aim of this analysis was to compare the outcome of patients who received veno-venous ECMO for COVID-19 and Influenza A H1N1 associated ARDS.
METHODS: This was a multicenter retrospective cohort study including adults with ARDS, receiving ECMO for COVID-19 and influenza A H1N1 pneumonia between 2009 and 2021 in seven Italian ICU. The primary outcome was any-cause mortality at 60 days after ECMO initiation. We used a multivariable Cox model to estimate the difference in mortality accounting for patients' characteristics and treatment factors before ECMO was started. Secondary outcomes were mortality at 90 days, ICU and hospital length of stay and ECMO associated complications.
RESULTS: Data from 308 patients with COVID-19 (N = 146) and H1N1 (N = 162) associated ARDS who had received ECMO support were included. The estimated cumulative mortality at 60 days after initiating ECMO was higher in COVID-19 (46%) than H1N1 (27%) patients (hazard ratio 1.76, 95% CI 1.17-2.46). When adjusting for confounders, specifically age and hospital length of stay before ECMO support, the hazard ratio decreased to 1.39, 95% CI 0.78-2.47. ICU and hospital length of stay, duration of ECMO and invasive mechanical ventilation and ECMO-associated hemorrhagic complications were higher in COVID-19 than H1N1 patients.
CONCLUSION: In patients with ARDS who received ECMO, the observed unadjusted 60-day mortality was higher in cases of COVID-19 than H1N1 pneumonia. This difference in mortality was not significant after multivariable adjustment; older age and longer hospital length of stay before ECMO emerged as important covariates that could explain the observed difference.
TRIAL REGISTRATION NUMBER: NCT05080933 , retrospectively registered.
参考来源
- Fanelli V, Giani M, Grasselli G, et al. Extracorporeal membrane oxygenation for COVID-19 and influenza H1N1 associated acute respiratory distress syndrome: a multicenter retrospective cohort study. Crit Care. 2022. PMID: 35123562. doi:10.1186/s13054-022-03906-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。